Top

News

09.14.21

QualityMetric’s SF-36v2 PRO Survey Contributes to EU’s ORCHESTRA SARS-CoV2 Impact Research

New York, September 14, 2021 — QualityMetric (QM), a leading global clinical outcomes assessments (COA) solutions provider and scientific consultancy specializing in patient-reported outcomes (PRO), has announced its collaboration  in ORCHESTRA, a three-year international research project led by the University of Verona to measure the impact of the SARS-CoV2 pandemic. The project involves thirty-seven total partners […]

06.28.21

Pulse Infoframe and QualityMetric Partner to Develop Novel Rare Disease Solution

QualityMetric and Pulse Infoframe announced today their partnership and vision to create the first scientifically validated rare disease instruments across conditions. Once deployed, these instruments will benefit not only rare disease patients and families, but also researchers and drug developers working to help this vastly underserviced population as they advance rare disease care and treatments.

Read More
03.08.21

Vesey Street Capital Partners-Backed QualityMetric Adds Angela Host as Chief Commercial Officer

Ms. Host’s distinguished career spans 20+ years, with progressively larger leadership roles in healthcare across life sciences, provider, and payer markets.

Read More
01.29.21

Vesey Street Capital Partners-Backed QualityMetric Adds John Hart as Chief Financial Officer

Mr. Hart will join the team led by Chief Executive Officer Garth “Gus” Gardner, who has been in that role since soon after the VSCP-led recapitalization of the company in August of 2020.

Read More
01.07.21

QualityMetric Co-authors New Qualitative Study on hATTR

QualityMetric’s own Kimberly Raymond, Andrew Lovley, and Michelle White co-author a new study on the humanistic burden of hereditary transthyretin (hATTR) amyloidosis from the patient’s perspective.

Read More
12.30.20

QualityMetric Co-authors Study Supporting Content Validity of the ACT

QualityMetric’s Vice President and Senior Scientist, Mark Kosinski, co-authors a study for determining whether the content of the Asthma Control Test (ACT) serves as a valid measure of asthma control.

Read More
12.15.20

How We Identify the Best PRO Tools for Medical Device Manufacturers

Our experts provide medical device clients with leading strategic measurement services, qualitative and quantitative research and patient journey studies, PRO outcomes analyses, rare disease research, and PRO regulatory support services.

Read More
11.15.20

QualityMetric Develops PROs for Determining Worldwide Impact of COVID-19

As pharma, biotech, medical device companies and academic researchers race to discover treatments for COVID-19, they require measurement and outcomes reporting for capturing real-world evidence.

Read More
09.15.20

A Letter to Our Customers

We want to inform you of a recent development that will allow us to enhance the services and support we provide.

Read More
09.11.20

Vesey Street Capital Partners Announces Gus Gardner as Chief Executive Officer of QualityMetric

Gardner’s appointment comes as the company seeks to build on its position as the preeminent provider of Patient Reported Outcomes (PRO) and Clinical Outcome Assessments (COA) solutions and services to healthcare and life sciences companies.

Read More